《大行報告》大摩下調中國中車(01766.HK)目標價至5元 評級「增持」
摩根士丹利發表報告指,中國中車(01766.HK)今年第三季純利25億元人民幣,按年跌20%,符合該行及市場預期,反映收入按年倒退13%,及毛利率按年收窄1.5個百分點。首三季計,集團純利按年下降5%至65億元人民幣,佔該行及市場今年全年預測分別60%及55%。
該行預期,集團盈利將在今年見底,並於明年強勁反彈,主要是受到疫情有更好控制,令鐵路設備業務復甦所支持。
大摩下調中國中車股份目標價,由6元降至5元,評級維持「增持」,並調低集團今年至2023年每股盈利預測14%至21%,以反映內地部分地區出現疫情,及乘客量惡化等原因,降低對中車第四季的投標及收入預測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.